Intrinsiqq
Universal Technical Institute Inc. logo

Universal Technical Institute Inc. (UTI) Insider Trading

Last 12 months

Insiders bought $335k and sold $10.9M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Executive Officer Jerome Alan Grant sold $3.91M on Jun 29, 22% of their stake, outside a plan.

Net open-market
−$10.6M
6 buys · 11 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
1 / 10
executives and directors
Last open-market buy
Sep 2026
Sep 28, 2026

Get an email when UTI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 28
    Robert Thomas Devincenzi
    Director · bought 1,000 at $19.68
    $20k
    0.7% of stake
  • Sep 21
    Robert Thomas Devincenzi
    Director · bought 1,000 at $19.83
    $20k
    0.7% of stake
  • Aug 27
    Robert Thomas Devincenzi
    Director · bought 1,000 at $21.80
    $22k
    0.7% of stake
  • Aug 25
    Robert Thomas Devincenzi
    Director · bought 1,000 at $21.77
    $22k
    0.7% of stake
  • Aug 12
    Robert Thomas Devincenzi
    Director · bought 1,000 at $25.95
    $26k
    0.7% of stake
  • Aug 10
    Robert Thomas Devincenzi
    Director · bought 8,000 at $28.21
    $226k
    5.7% of stake
  • Jun 29No plan
    Jerome Alan Grant
    Chief Executive Officer · sold 94,500 at avg $41.40
    $3.91M
    22% of stake
  • Jun 22No plan
    Kevin Prehn
    Concorde Division President · sold 4,545 at $40.00
    $182k
    14% of stake
  • Jun 8No plan
    Coliseum Capital Partners, L.p.
    Large holder · sold 3,000,000 at $41.40
    $124M
    76% of stake
  • Jun 5No plan
    Christine Kline
    Senior Vice President and CAO · sold 3,500 at $44.42
    $155k
    7.5% of stake
  • May 11No plan
    Linda J Srere
    Director · sold 15,000 at $36.59
    $549k
    11% of stake
  • Mar 27No plan
    Christopher E. Kevane
    EVP and Chief Legal Officer · sold 23,654 at $37.55
    $888k
    22% of stake
  • Mar 17No plan
    George W. Brochick
    Director · sold 5,000 at $36.59
    $183k
    14% of stake
  • Mar 6No plan
    Shannon Lei Okinaka
    Director · sold 10,000 at $34.74
    $347k
    34% of stake
  • Mar 4No plan
    Todd A Hitchcock
    EVP/COO · sold 16,500 at $37.33
    $616k
    14% of stake
  • Mar 2No plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 52,671 at avg $37.04
    $1.95M
    19% of stake
  • Feb 27No plan
    Jerome Alan Grant
    Chief Executive Officer · sold 60,040 at $34.95
    $2.1M
    12% of stake
  • Feb 13No plan
    Carolyn Ann Frank
    SVP/Chief HR Officer · sold 1,750 at $30.08
    $53k
    5.5% of stake
  • Dec 3, 2025 – Dec 5, 2025
    Coliseum Capital Management, LLC
    Large holder · bought 547,066 at avg $25.01
    $13.7M
    7.8% of stake
  • Dec 1, 2025 – Dec 2, 2025
    Coliseum Capital Management, LLC
    Large holder · bought 708,107 at avg $24.19
    $17.1M
    13% of stake
  • Aug 12, 2025
    Robert Thomas Devincenzi
    Director · bought 10,000 at avg $25.40
    $254k
    7.9% of stake
  • May 27, 2025No plan
    Christopher S Shackelton
    Director · sold 500,000 at $35.00
    $17.5M
    16% of stake
  • May 15, 2025No plan
    Todd A Hitchcock
    EVP/COO · sold 27,500 at avg $33.36
    $917k
    25% of stake
  • May 13, 2025No plan
    George W. Brochick
    Director · sold 6,000 at $31.84
    $191k
    16% of stake
  • May 12, 2025No plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 50,000 at $33.84
    $1.69M
    23% of stake
  • May 12, 2025No plan
    Christopher E. Kevane
    EVP and Chief Legal Officer · sold 29,400 at avg $34.12
    $1M
    29% of stake
  • May 12, 2025No plan
    Jerome Alan Grant
    Chief Executive Officer · sold 56,492 at $33.80
    $1.91M
    14% of stake
  • May 12, 2025No plan
    Coliseum Capital, LLC
    Large holder · sold 1,929,488 at $32.95
    $63.6M
    37% of stake
  • Apr 15, 202510b5-1 plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 97 at $28.05
    $3k
    <0.1% of stake
  • Apr 9, 202510b5-1 plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 208 at $28.05
    $6k
    0.2% of stake
  • Mar 27, 2025No plan
    Coliseum Capital, LLC
    Large holder · sold 1,000,000 at $25.35
    $25.4M
    16% of stake
  • Mar 21, 202510b5-1 plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 10,000 at avg $26.95
    $270k
    6.0% of stake
  • Mar 19, 2025 – Mar 20, 202510b5-1 plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 49,695 at avg $27.85
    $1.38M
    23% of stake
  • Mar 17, 2025 – Mar 18, 202510b5-1 plan
    Sherrell Smith
    EVP, Chief Academic Officer · sold 70,000 at avg $26.83
    $1.88M
    27% of stake
  • Feb 26, 2025No plan
    George W. Brochick
    Director · sold 8,000 at $27.59
    $221k
    19% of stake
  • Feb 10, 2025No plan
    Christopher S Shackelton
    Director · sold 704,881 at $28.20
    $19.9M
    10% of stake
  • Dec 2, 2024No plan
    Adam Gray
    Director · sold 2,483,579 at $25.10
    $62.3M
    27% of stake
  • Nov 27, 2024No plan
    Kenneth R Trammell
    Director · sold 30,000 at $25.92
    $778k
    19% of stake
  • Nov 26, 2024No plan
    Linda J Srere
    Director · sold 30,000 at $25.53
    $766k
    18% of stake
  • Nov 25, 2024No plan
    Robert Thomas Devincenzi
    Director · sold 150,000 at avg $25.45
    $3.82M
    55% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch UTI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Educational Services

Spot a number that looks wrong? Check it in UTI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing UTI

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.